Globus Medical, which has a market cap of $11.9bn, will buy all Nevro ... stimulator systems, for example, gained access to a wider market after winning FDA approval for non-surgical back pain ...

Nevro’s comprehensive HFX spinal cord stimulation (SCS) platform includes the Senza SCS system and support services for the treatment of chronic pain of the trunk and limb and painful diabetic ...

life-changing solutions for the treatment of chronic pain. “We are excited to begin the journey of accelerating market penetration of Nevro’s differentiated high-frequency technology and ...

It has been about a month since the last earnings report for Nevro (NVRO). Shares have added about 0.9% in that time frame, outperforming the S&P 500. Will the recent positive trend continue ...